Community weight management support in Dorset – Tirzepatide (Mounjaro)
In line with NICE guidance, the new weight management ‘Tirzepatide’ medication (brand name Mounjaro®) has been approved for use in the NHS. Tirzepatide will be available to NHS patients nationally from 23 June and locally from autumn 2025.
In Dorset around 1,000 people currently qualify for the medication based on national eligibility criteria, which states individuals must:
-
Have a body mass index (BMI) of 40 kg/m² or more (or 37.5 kg/m² for people from minority ethnic family backgrounds) and have at least four of the following long-term conditions:
-
Non-diabetic hyperglycaemia or type 2 diabetes
-
Hypertension (high blood pressure)
-
Dyslipidaemia
-
Established cardiovascular disease
-
Obstructive sleep apnoea
More information is available on the NHS Dorset website.
